Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients

Immunobiology

Volumn 200, Issue 2, 1999, Pages 295-305

  Mühlbacher, Moritz ^a   Spruth, Martin ^a   Siegel, Felix ^a   Zangerle, Robert ^b   Dierich, Manfred P ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Universitatsklinik fuer Dermatologie und Venerologie Innsbruck   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PEPTIDE;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; COMPARATIVE STUDY; GENETIC CONSERVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ENVELOPE;

EID: 17144474478     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0171-2985(99)80078-3     Document Type: Article

References (37)

1. PANTALEO, G. and A. S. FAUCI. 1996. Immunopathogenesis of HIV infection. Annu. Rev. Microbiol. 50: 825.
2. GNANN, J. W., Jr., J. A. NELSON, and M. B. OLDSTONE. 1987. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J. Virol. 61: 2649.
3. DOWBENKO, D., G. NAKAMURA, C. FENNIE, C. SHIMASAKI, L. RIDDLE, R. HARRIS, T. GREGORY, and L. LASKY. 1998. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J. Virol. 62: 4703.
4. GOUDSMIT, J., R. H. MELOEN, R. BRASSEUR, and F. BARIN. 1989. Human B-cell epitopes of HIV-2 transmembrane protein are similarly spaced as in HIV-1. J. Acquir. Immune. Defic. Syndr. 2: 297.
5. NEURATH, A. R., N. STRICK, and E. S. LEE. 1990. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19-to 36-residue) synthetic peptides. J. Gen. Virol. 71: 85.
6. PASQUALI, J. L., M. P. KIENY, H. KOLBE, D. CHRISTMANN, and A. M. KNAPP. 1990. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein. AIDS Res. Hum. Retroviruses 6: 1107.
7. WARREN, R. Q., H. WOLF, R. A. ZAJAC, R. N. BOSWELL, P. KANDA, and R. C. KENNEDY. 1991. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels. J. Clin. Immunol. 11: 13.
8. Xu, J. Y., M. K. GOTNY, T. PALKER, S. KARWOWSKA, and S. ZOLLA PAZNER. 1991. Epitope mapping of two immunodominent domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65: 4832.
9. HO, D. D., M. S. FUNG, Y. Z. CAO, X. L. LI, C. SUN, T. W. CHANG, and N. C. SUN. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88: 8949.
10. HO, D. D., M. S. FUNG, H. YOSHIYAMA, Y. CAO, and J. E. ROBINSIN. 1992. Discontinuous epitopes on gp120 important in HIV-1 neutralization. AIDS Res. Hum. Retroviruses 8: 1337.
11. SIEGEL, F., S. NORLEY, S. HARTUNG, and R. KURTH. 1992. B-cell epitope mapping of the entire SIVagm envelope glycoprotein including fine mapping of immunogenic regions. J. Acquir. Immune Defic. Syndr. 5: 583.
12. SATTENTAU, Q. J. and J. P. MOORE. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182:185.
13. SATTENTAU, Q. J., S. ZOLLA PAZNER, and P. POIGNARD. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206: 713.
14. LYERLY, H. K., D. L. REED, T. J. MATTHEWS, A. J. LANGLOIS, P. A. AHEARNE, S. R. PETTEWAY, Jr., and K. J. WEINHOLD. 1987. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res. Hum. Retroviruses 3: 409.
15. ROBINSON, W. E., Jr., D. C. MONTEFIORI, D. H. GILLESPIE, and W. M. MITCHELL. 1989. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J. Acquir. Immune Defic. Syndr. 2: 33.
16. JUINE, R. A., S. Z. SCHADE, M. J. BANKOWSKI, M. KUHNS, A. MCNAMARA, T. F. LINT, A. L. LANDAY, and G. T. SPEAR. 1991. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 5: 269.
17. POSNER, M. R., H. S. ELBOIM, T. CANNON, L. CAVACINI, and T. HIDESHIMA. 1992. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res. Hum. Retroviruses 8: 553.
18. RABENSTEIN, M. D. and Y. K. SHIN. 1996. HIV-1 gp41 tertiary structure studied by EPR spectroscopy. Biochemistry 35:13922.
19. CHAN, D. C., D. FASS, J. M. BERGER, and P. S. KIM. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263.
20. WILLEY, R. L., J. S. BONIFACINO, B. J. POTTS, M. A. MARTIN, and R. D. KLAUSNER. 1988. Biosynthesis, cleavage, and degradation of the human immunodeficiency virus I envelope glycoprotein gp160. Proc. Natl. Acad. Sci. USA 85: 9580.
21. WONG, M. T., R. Q. WARREN, S. A. ANDERSON, M. J. DOLAN, C. W. HENDRIX, S. P. BLATT, G. P. MELCHER, R. N. BOSWELL, and R. C. KENNEDY. 1993. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects. J. Infect. Dis. 168: 1523.
22. BINLEY, J. M., P. J. KLASSE, Y. Z. CAO, I. JONES, M. MARKOWITZ, D. D. HO, and J. P. MOORE. 1997. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol. 71: 2799.
23. FOUTS, T. R., J. M. BINLEY, A. TRKOLA, J. E. ROBINSON, and J. P. MOORE. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71: 2779.
24. BURTON, D. R., J. PYATI, R., KODURI, S. J. SHARP, G. B. THORNTON, P. W. PARREN, L. S. SAWYER, R. M. HENDRY, N. DUNLOP, P. L. NARA et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024.
25. CONLEY, A. J., J. A. KESSLER, L. J. BOOTS, J. S. TUNG, B. A. ARNOLD, P. M. KELLER, A. R. SHAW, and E. A. EMINI. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAm-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91: 3348.
26. PURTSCHER, M., A. TRKOLA, G. GRUBER, A. BUCHACHER, R. PREDL, F. STEINDL, C. TAUER, R. BERGER, N. BARRETT, A. JUNGBAUER et al. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10: 1651.
27. MUSTER, T., R. GUINEA, A. TRKOLA, M. PURTSCHER, A. KLIMA, F. STEINDL, P. PALESE, and H. KATINGER. 1994. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68: 4031.
28. TRKOLA, A., A. B. POMALES, H. YUAN, B. KORBER, P. J. MADDON, G. P. ALLAWAY, H. KATINGER, C. F. BARBAS, D. R. BURTON, D. D. Ho et al. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69: 6609.
29. D'SOUZA, M. P., G. MILMAN, J. A. BRADAC, D. MCPHEE, C. V. HANSON, and R. M. HENDRY. 1995. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 9: 867.
30. D'SOUZA, M. P., D. LIVNAT, J. A. BRADAC, S. H. BRIDGES, Y. BRYSON, C. HANSON, T. MATTHEWS, M. MOORE, A. TRKOLA, S. ZOLLAPAZNER, M. GORNY, D. BURTON, T. MERIGAN, J. McNNAMARA, M. NORCROSS, M. POSNER, R. ROBINSON, N. VIRANKIKETTER, C. BARBAS, P. PARREN, and H. KATINGER. 1997. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175:1056.
31. TRKOLA, A., M. PURTSCHER, T. MUSTER, C. BALLAUN, A. BUCHACHER, N. SULLIVAN, K. SRINIVASAN, J. SODROSKI, J. P. MOORE, and H. KATINGER. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100.
32. MUSTER, T., F. STEINDL, M. PURTSCHER, A. TRKOLA, A. KLIMA, G. HIMMLER, F. RUKER, and H. KATINGER. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67: 6642.
33. BROLIDEN, P. A., A. VON GEGERFELT, P. CLAPHAM, J. ROSEN, E. M. FENYO, B. WAHREN, and K. BROLIDEN. 1992. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. USA 89: 461.
34. PINTER, C., A. G. SICCARDI, L. LOPALCO, R. LONGHI, and A. CLIVIO. 1995. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS Res. Hum. Retroviruses 11: 971.
35. EBENBICHLER, C. F., N. M. THIELENS, R. VORNHAGEN, P. MARSCHANG, G. J. ARLAUD, and M. P. DIERICH. 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174. 1417.
36. + lymphocytes in HIV infection. Clin. Immunol. Immunopathol. 72: 328.
37. NEURATH, A. R., N. STRICK, P. TAYLOR, P. RUBINSTEIN, and C. E. STEVENS. 1990. Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistance to disease development. AIDS Res. Hum. Retroviruses 6: 1183.